Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

Research and Innovation Action · Running

THEODORA immunoTHErapies targeting neOgenes in paeDiatric and adOlescent saRcomAs

Coordinator
Institut Curie, France
Runs
1 September 2026 to 29 February 2032
Status
Running
EU funding
€8.7m
Total cost
—
Partners
8 organisations in 5 countries
Type
Research and Innovation Action
Grant agreement
101288100

What the project is doing

In the project's own words, from its summary on CORDIS.

THEODORA addresses the unmet need for effective and less toxic therapies for paediatric and adolescent fusion-positive sarcomas, particularly Ewing sarcoma (EwS), where 2-year survival at relapse remains below 10%. Building on the recent discovery of oncogenic chimeric transcription factors-driven “neogenes” as a novel class of shared, tumour-specific antigens, the project aims to establish a European master protocol framework to evaluate innovative immunotherapies in early-stage clinical trials.

The first substudy will be the first-in-class and first-in-child evaluation of disruptive TCR-T cells engineered to target an EwS-specific neogene. Innovative monitoring tools will be implemented, including liquid biopsy, AI-enhanced imaging, and immune profiling together with statistical modelling, to track responses and resistance mechanisms. Patient-reported outcomes and real-time feedback loops will capture the child’s and family’s experience, ensuring a patient-centred and socially responsible approach.

Data will be managed under FAIR principles and shared through UNCAN.eu, creating a reference use case for European paediatric oncology. THEODORA brings together four leading paediatric oncology centres with proven expertise in early-phase clinical trials and translational research, alongside immunologists, data scientists, SSH experts, and patient advocates, to accelerate next-generation therapies. A core focus is advancing TCR-T product development through process optimisation, manufacturing innovation, and regulatory readiness to ensure feasibility and accessibility.

Endorsed by ITCC and embedded in EU CAN KIDS and Euro Ewing Consortium networks, the project fully aligns with Horizon Europe Cancer Mission goals. By establishing a sustainable, multinational framework for innovative trials, THEODORA will deliver the first clinical evidence for TCR-T–based targeted immunotherapies in EwS and pave the way for broader application across OCTF-driven sarcomas. This action is part of the Cancer Mission cluster of projects on “Diagnosis and Treatment - innovative clinical trials for paediatric cancer"".""

Topics

Who is involved

OrganisationCityCountryRole
Institut CurieParisFranceCoordinator
Biobanks and Biomolecular Resources Research Infrastructure Consortium (bbmri-Eric)GrazAustriaParticipant
Childhood Cancer International Europe PatientInnen Organisation für von an Krebs erkrankten Kindern, Jugendlichen und deren Familien in EuropaViennaAustriaParticipant
Seeding Science SprlOttignies-Louvain-La-NeuveBelgiumParticipant
Ruprecht-Karls-Universitaet HeidelbergHeidelbergGermanyParticipant
Universitatsklinikum HeidelbergHeidelbergGermanyThird party
Institut Gustave RoussyVillejuifFranceParticipant
Prinses Maxima Centrum Voor Kinderoncologie BVUtrechtNetherlandsParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI